OCUL - オキュラ―・セラピュ―ティクス （Ocular Therapeutix Inc.）

The trading price of Ocular Therapeutix Inc. (NASDAQ:OCUL) closed higher on Friday, June 17, closing at $3.74, 9.04% higher than its previous close. >> 5 Best Growth Stocks for 2022 << >> 5 Best Growth Stocks for 2022 << Traders who pay close attention to intraday price movement should know that it fluctuated between $3.43 … Here’s Why Ocular Therapeutix Inc. (NASDAQ: OCUL) Is A Good Stock To Buy Right Now Read More »

BEDFORD, Mass.--(BUSINESS WIRE)--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, announced senior leadership changes to strengthen the Company’s alignment around the development of its late-stage ophthalmology product portfolio. The realignment was affected to enhance Ocular’s ability to execute its strategy of building a comprehensive portfolio of a

Ocular Therapeutix Inc. (NASDAQ:OCUL) shares, rose in value on Friday, 06/03/22, with the stock price down by -1.26% to the previous day’s close as strong demand from buyers drove the stock to $3.14. Actively observing the price movement in the last trading, the stock closed the session at $3.18, falling within a range of $3.10 … Ocular Therapeutix Inc. (NASDAQ: OCUL) Shares Are Set To Rise By 2022 Read More »

Ocular Therapeutix, Inc. (Nasdaq: OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will present in a fireside chat at the Jefferies Healthcare Conference on Wednesday, June 8, 2022 at 8:00 AM ET at the Marriott Marquis in New York, NY. In addition to the presentation,

BEDFORD, Mass.--(BUSINESS WIRE)--Ocular Therapeutix, Inc. (Nasdaq: OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will present in a fireside chat at the Jefferies Healthcare Conference on Wednesday, June 8, 2022 at 8:00 AM ET at the Marriott Marquis in New York, NY. In addition to the presentation, the management team will host investor meetings. Investors pa

Ocular Therapeutix (OCUL) is scheduled to announce Q1 earnings results on Monday, May 9th, after market close.The consensus EPS Estimate is -$0.20 (+16.7% Y/Y) and the consensus…

Ocular Therapeutix, Inc. , a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, announced two… | May 3, 2022

Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative thera

Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, announced two scientific presentations at the American Society of Gene & Cell Therapy (ASGCT) 25th Annual Meeting being held May 16-19, 2022 in Washington, D.C. and virtually. “We have demonstrated

DEXTENZA® 0.4 mg Recorded Net Quarterly Sales of $12.2 Million, Representing Year-Over-Year Growth of 77% Creating New Business Unit Focused on Optimizing the Commercial Opportunity for… | February 28, 2022

Ocular Therapeutix press release (NASDAQ:OCUL): Q4 GAAP EPS of -$0.23 in-line.Revenue of $12.31M (+67.5% Y/Y) misses by $2.13M.

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today reported financial results for the quarter and year ended December 31, 2021, and provided updates on its ophthalmology pipeline. “Ocular has had another strong quarter and a productive year,” said Antony Mattessich, President and Chief Executive Officer. “Our comme

Companies Reporting Before The Bell • Lexicon Pharmaceuticals (NASDAQ: LXRX ) is estimated to report earnings for its fourth quarter. • Praxis Precision Medicine (NASDAQ: PRAX ) is likely to report earnings for its fourth quarter. • Blackstone Secured (NYSE: BXSL ) is likely to report quarterly earnings at $0.59 per share on revenue of $171.69 million. • Mersana Therapeutics (NASDAQ: MRSN ) is estimated to report earnings for its fourth quarter. • Partner Communications Co (NASDAQ: PTNR ) is expected to report earnings for its fourth quarter. • Daqo New Energy (NYSE: DQ ) is expected to report quarterly earnings at $4.58 per share on revenue of $698.65 million. • Easterly Government Props (NYSE: DEA ) is likely to report quarterly earnings at $0.10 per share on revenue of $72.20 million. • Aurinia Pharmaceuticals (NASDAQ: AUPH ) is expected to report earnings for its fourth quarter. • Kosmos Energy (NYSE: KOS ) is estimated to report quarterly earnings at $0.15 per share on revenue of $380.